Key result
GLP-1 agents improve LVEF by ~2.5% and reduce infarct size vs placebo after AMI PCI.
Why the study?
The cardioprotective properties of GLP-1 receptor agonists against reperfusion injury in AMI patients remain unclear.
Do glucagon-like peptide-1 (GLP-1) receptor agonists improve LVEF and reduce infarct size in patients with acute myocardial infarction undergoing PCI?
Comparison
GLP-1 receptor agonists vs placebo
Design
Meta-analysis of randomized controlled trials
Authors
Loading...
GLP-1 agonists may limit reperfusion injury in AMI; leaves open impact on hard clinical outcomes.
Meta-Analysis (n=800)
Do glucagon-like peptide-1 (GLP-1) receptor agonists improve LVEF and reduce infarct size in patients with acute myocardial infarction undergoing PCI?
Mean Difference: 2.46 (95% CI 0.23–4.7)
In patients with acute myocardial infarction undergoing PCI, GLP-1 receptor agonists significantly improve LVEF and reduce infarct size, though they are associated with increased gastrointestinal adverse events.
Huang et al. (2017) conducted a meta-analysis in acute myocardial infarction (n=800). GLP-1 agents vs. placebo was evaluated on left ventricular ejection fraction (LVEF) (MD 2.46, 95% CI 0.23-4.70). In patients with AMI undergoing PCI, GLP-1 agents improved left ventricular ejection fraction by 2.46% (95% CI 0.23-4.70) and reduced infarct size compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: